5'-脱氧氟尿苷治疗复发性乳腺癌患者的临床试验
[Clinical trial of 5'-DFUR in patients with recurrent breast cancer].
作者信息
Morimoto T, Komaki K, Yamakawa T, Tanaka T, Konishi Y, Uomine Y, Miki H, Ooshimo K, Monden Y
机构信息
2nd Dept. of Surgery, School of Medicine, University of Tokushima.
出版信息
Gan To Kagaku Ryoho. 1988 Oct;15(10):2983-9.
5'-DFUR was administered orally to recurrent breast cancer patients at a daily dosage of 1,200 mg given 3 times a day for more than 8 weeks. Out of 16 evaluable cases, 1 CR, 5 PR, 5 NC and 5 PD were observed, and the overall response rate was 37.5%. There was no significant difference in the response rate between the patient with or without prior fluorinated pyrimidine therapy, or between sites of the lesion. Toxic effects consisted of gastrointestinal toxicity such as diarrhea (25%), anorexia (12.5%), abdominal pain (12.5%) and nausea and vomiting (6.3%). No other severe side effect was observed. These results suggest that 5'-DFUR can be useful for the treatment of breast cancer.
对复发性乳腺癌患者口服5'-DFUR，每日剂量为1200毫克，分3次服用，持续8周以上。在16例可评估病例中，观察到1例完全缓解（CR）、5例部分缓解（PR）、5例疾病稳定（NC）和5例疾病进展（PD），总缓解率为37.5%。既往接受或未接受过氟嘧啶治疗的患者之间，以及病变部位之间的缓解率无显著差异。毒性作用包括胃肠道毒性，如腹泻（25%）、厌食（12.5%）、腹痛（12.5%）以及恶心和呕吐（6.3%）。未观察到其他严重副作用。这些结果表明，5'-DFUR可用于乳腺癌的治疗。
Zotero 插件